Geniposide (Iridoid Glycoside · GLP-1R Agonism · Hepatoprotective · Neuroprotective)
| Compound | Geniposide |
| Chemical class | Terpenoid — Iridoid Glycoside (Seco-iridoid) |
| CAS | 24512-63-8 |
| Primary source | Gardenia jasminoides (Cape jasmine / Gardenia fruit) |
| Key applications | Hepatoprotective, neuroprotective, anti-inflammatory, anti-diabetic |
| Claim strength | Moderate |
| Typical form | Geniposide 98% extract (Gardenia); Crocin 20%/10% (Gardenia) — co-extracted |
| Buy from Herbuno |
Name origin: From Gardenia jasminoides var. genipiflora. Geniposide is a seco-iridoid glycoside — the glycosidic form of genipin (the aglycone). Genipin itself is a well-known natural cross-linking agent for proteins and chitosan used in biomedical applications. Traditional use: Gardenia fruit (Zhi Zi in TCM) is one of the most frequently prescribed herbs in TCM for heat-clearing, liver-calming, haemostatic, and anti-inflammatory applications. The yellow pigment from Gardenia (crocetin/crocin fraction) is also used as a food colourant. Research trajectory: Geniposide has attracted significant research for hepatoprotective activity (NF-κB suppression, TGF-β1 inhibition, anti-fibrotic), neuroprotective effects in Alzheimer’s disease models (GLP-1R activation pathway), anti-inflammatory mechanisms, and insulin secretagogue activity. GLP-1 receptor agonism by geniposide is a particularly differentiated mechanism with implications for diabetes and neuroprotection. Commercial source: Geniposide 98% Extract Powder and Crocin 20%/10% (Gardenia) are commercially available from Gardenia jasminoides extraction. See sourcing options below.
Evidence for Geniposide Applications
GLP-1 receptor agonism — diabetes and neuroprotection: Geniposide activates the glucagon-like peptide-1 receptor (GLP-1R), the same receptor targeted by pharmaceutical GLP-1 agonist drugs (semaglutide, liraglutide). GLP-1R activation promotes insulin secretion, reduces glucagon, and has documented neuroprotective effects (reduces amyloid-beta in AD models, protects dopaminergic neurons). This mechanism is pharmacologically significant — GLP-1R agonism from a natural iridoid glycoside is a differentiated and commercially relevant positioning. Claim strength: Moderate (mechanism well-characterised; human clinical data limited).
Hepatoprotective and anti-fibrotic: Geniposide inhibits TGF-β1-induced hepatic stellate cell activation, reduces hepatic collagen deposition, and protects against CCl4-induced and NAFLD-associated liver injury in animal models. NF-κB suppression and Nrf2 activation are confirmed mechanisms. Claim strength: Moderate.
Neuroprotective — Alzheimer’s disease models: Geniposide reduces amyloid-beta aggregation, inhibits tau phosphorylation, and reduces neuroinflammation in AD animal models. The GLP-1R pathway contributes to neuroprotection alongside direct anti-inflammatory effects. Small human clinical data from Gardenia extract preparations in TCM contexts are reported. Claim strength: Moderate.
Anti-inflammatory: Inhibits NF-κB, reduces TNF-α, IL-6, and IL-1β across macrophage and epithelial models. In vivo anti-inflammatory efficacy confirmed in arthritis, colitis, and neuroinflammation animal models. Claim strength: Moderate.
Browse Standardised Extract Powders →
Dosage & Formulator Specification
No established human clinical dose for isolated geniposide. Traditional TCM Gardenia fruit preparation: 6–10 g/day dried fruit (delivering approximately 10–30 mg geniposide based on typical 0.1–0.3% geniposide content of dried Gardenia fruit). Herbuno’s Geniposide 98% allows precise dosing — animal neuroprotective and anti-diabetic studies translate to approximately 20–100 mg/day human equivalent doses, achievable with concentrated extract. Note: geniposide is hydrolysed in the gut to genipin (the aglycone) and glucose — genipin has direct pharmacological activity and also serves as a cross-linking agent at high concentrations. At supplement doses, genipin cross-linking effects are not considered physiologically significant.
Frequently Asked Questions — Geniposide
What is the GLP-1R mechanism and why is it significant for geniposide?
GLP-1 (glucagon-like peptide-1) is an incretin hormone that stimulates insulin secretion, reduces glucagon, slows gastric emptying, and promotes satiety. GLP-1R agonist pharmaceutical drugs (semaglutide/Ozempic, liraglutide/Victoza) have become blockbuster medications for type 2 diabetes and obesity. Geniposide activates GLP-1R through a different binding mechanism from GLP-1 itself — making it the first identified natural small-molecule GLP-1R agonist. This positions geniposide as a scientifically relevant natural compound for metabolic health and neuroprotection formulations, though its potency and pharmacokinetics are far below pharmaceutical GLP-1 agonist drugs.
Is geniposide from Gardenia the same as the genipin used as a cross-linking agent?
Geniposide is the glycoside (glucose attached); genipin is the aglycone formed by hydrolysis of geniposide. Genipin is widely used in biomaterials and tissue engineering as a natural cross-linker for collagen, chitosan, and gelatin — it reacts with primary amines and is much less toxic than synthetic cross-linkers like glutaraldehyde. At the very low concentrations produced from geniposide hydrolysis during oral supplement digestion, genipin cross-linking effects are not considered physiologically significant.
What is the relationship between geniposide and crocin/croccetin in Gardenia?
Gardenia fruit contains two distinct compound families: iridoids (geniposide, genipin) responsible for hepatoprotective and neuroprotective activity, and carotenoids (crocin, crocetin, croccetin) responsible for the bright yellow pigment and their own documented antidepressant and neuroprotective activity. Both Geniposide 98% (iridoid fraction) and Crocin 20%/10% (carotenoid fraction) from Gardenia are commercially available — allowing formulators to specify either or both depending on the application.
Can geniposide be positioned as a natural alternative to GLP-1 drugs for weight management?
No — geniposide should not be positioned as an alternative to pharmaceutical GLP-1R agonists. The pharmacological potency and dose-response characteristics are incomparable — drugs like semaglutide achieve sustained GLP-1R activation at picomolar plasma concentrations that are orders of magnitude more potent than dietary supplement achievable geniposide concentrations. Appropriate positioning: "studied for GLP-1 receptor modulation" or "may support healthy blood glucose metabolism" — not as a drug substitute or weight loss agent.
Related compounds: Catalpol, Aucubin, Harpagoside, Camphor
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery